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Cyclic AMP (cAMP) is an important second messenger signaling molecule that controls a wide variety of
eukaryotic and prokaryotic responses to extracellular cues. For cAMP-dependent signaling pathways to be
effective, the intracellular cAMP concentration is tightly controlled at the level of synthesis and degradation.
In the opportunistic human pathogen Pseudomonas aeruginosa, cAMP is a key regulator of virulence gene
expression. To better understand the role of cAMP homeostasis in this organism, we identified and charac-
terized the enzyme CpdA, a putative cAMP phosphodiesterase. We demonstrate that CpdA possesses 3,5-
cAMP phosphodiesterase activity in vitro and that it utilizes an iron-dependent catalytic mechanism. Deletion
of cpdA results in the accumulation of intracellular cAMP and altered regulation of P. aeruginosa virulence
traits. Further, we demonstrate that the cAMP-dependent transcription factor Vfr directly regulates cpdA
expression in response to intracellular cAMP accumulation, thus providing a feedback mechanism for con-
trolling cAMP levels and fine-tuning virulence factor expression.
The second messenger signaling molecule 3,5-cyclic AMP
(cAMP) plays diverse and vital roles in multiple cellular
processes in both eukaryotes and prokaryotes (4, 7). Intra-
cellular cAMP levels are tightly controlled, and homeostasis
is achieved by balancing cyclic nucleotide synthesis with deg-
radation. Cyclic AMP is synthesized by the enzyme adenylate
cyclase (AC) in response to intracellular and extracellular cues.
ACs are ubiquitous in nature, and six structurally distinct
classes have been identified (47, 49). Genome sequencing has
revealed that these enzymes are widely distributed among bac-
teria and that many species possess multiple ACs. For most
bacterial species, however, the cellular processes that are af-
fected by AC activity, and thus the biological role(s) of cAMP,
have yet to be defined.
Cyclic AMP is a stable, membrane-impermeable molecule;
in order to maintain homeostasis and to reset cAMP signaling
cascades following AC activation, signal attenuation is neces-
sary. This function can be achieved through degradation of
cAMP to 5-AMP by the enzyme cyclic 3,5-AMP phospho-
diesterase. Like ACs, cyclic nucleotide phosphodiesterases are
found in all branches of life and encompass a family of en-
zymes that are grouped into three classes based on their pri-
mary amino acid sequence: class I (eukaryotes), class II (Sac-
charomyces cerevisiae, Schizosaccharomyces pombe, Candida
albicans, Dictyostelium discoideum, and Vibrio fischeri), and
class III (most bacteria). Class III enzymes contain highly con-
served amino acid residues and secondary structural elements
that are homologous to those of purple acid phosphatases and
other dimetallophosphoesterases (41). Although the exact cat-
alytic mechanism of purple acid phosphatases is unknown,
their activity requires the presence of two active-site metal ions
(Fe3 and Fe2, Zn2, or Mn2). Biochemical analyses of
cAMP phosphodiesterases from Escherichia coli, Mycobacte-
rium tuberculosis, and Anabaena sp. strain PCC 7120 indicate a
similar requirement, suggesting that the structural and func-
tional organization of the catalytic site of class III cyclic nu-
cleotide phosphodiesterases is similar to that of the purple acid
phosphatases (15, 21, 46).
E. coli possesses the best-characterized bacterial cAMP-
dependent signaling system, which primarily controls the
metabolic response to environmental carbon availability.
Cyclic AMP acts as a positive allosteric regulator of the cAMP-
dependent transcriptional regulator cyclic AMP receptor pro-
tein (CRP) (7). The cAMP-CRP complex regulates the expres-
sion of more than 100 genes and operons, many of which are
involved in the transport and catabolism of carbon compounds
(17). E. coli possesses a single class III cyclic 3,5-AMP phos-
phodiesterase (CpdA). The activity of this enzyme has been
characterized in vitro (21, 33, 34); however, its global role in
cAMP homeostasis and signaling has not been examined.
In contrast to E. coli, where cAMP is involved in metabolite
repression, cAMP plays a critical role in controlling virulence
in the opportunistic human pathogen Pseudomonas aeruginosa
(51, 59). P. aeruginosa is an environmental bacterium capable
of causing a variety of life-threatening infections in immuno-
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compromised individuals and those receiving critical care (10).
In addition, P. aeruginosa is the primary cause of chronic de-
bilitating lung infection in individuals with cystic fibrosis. Cyclic
AMP serves as an allosteric regulator of the transcription fac-
tor Vfr, a member of the CRP family (56). Together, cAMP
and Vfr directly or indirectly regulate the expression of nu-
merous genes encoding virulence factors such as ToxA (exo-
toxin A or ETA), a type III secretion system (T3SS) and its
effectors (ExoS, ExoT, and ExoY), protease IV, and type IV
pili (5, 9, 56, 59). Whole-genome expression profiling revealed
that P. aeruginosa mutants defective in cAMP synthesis or
lacking vfr produced nearly identical transcriptomes, affecting
the expression of approximately 200 genes, many of which are
known to be involved in virulence (59). These studies suggest
that Vfr activity is ultimately dependent on the availability of
cAMP. Thus, characterization of the mechanisms that regulate
cAMP homeostasis in P. aeruginosa will provide a clearer un-
derstanding of how this bacterial pathogen establishes and
maintains infection.
In P. aeruginosa, intracellular cAMP is synthesized by two
adenylate cyclases, designated CyaA and CyaB (59). CyaA
shares homology with the class I AC of E. coli (27), and CyaB
is a member of the class III family, widely distributed in both
eukaryotes and prokaryotes (49). P. aeruginosa mutants lacking
either cyaA or cyaB have reduced intracellular levels of cAMP;
however, the contribution of CyaB to the cAMP pool is sub-
stantially greater than that of CyaA (59). Elimination of CyaB
alone results in attenuation of virulence in an adult mouse
model of acute pneumonia (51).
Although cAMP phosphodiesterase activity was previ-
ously detected in the cytoplasmic fraction of crude cell ly-
sates of P. aeruginosa (48), the enzyme(s) involved has not
been identified. In the present study, we identify a single
putative cAMP phosphodiesterase-encoding gene (PA4969)
within the P. aeruginosa genome. We demonstrate that the
purified gene product, which we have designated CpdA, has
cyclic 3,5-AMP phosphodiesterase activity in vitro. In addi-
tion, we show that P. aeruginosa CpdA plays a significant role
in cAMP homeostasis in vivo and is specifically required for
virulence factor regulation. Finally, we found that Vfr directly
activates expression of cpdA in response to elevated intracel-
lular cAMP, thus providing a complex multilayered mechanism
for controlling cAMP homeostasis in P. aeruginosa.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. For routine passage, E.
coli and P. aeruginosa strains were grown at 37°C in LB medium (Difco). pMMB-
based expression plasmids were maintained in P. aeruginosa with 150 g/ml
carbenicillin (Cb) except where noted. Bacterial growth in broth culture was
assessed by optical density at 600 nm (OD600), and doubling times during expo-
nential phase growth were calculated based on time required for 2-fold increases
in the OD600.
The strains and plasmids used in this study are listed in Table 1. Chromosomal
deletion of P. aeruginosa cpdA (codons 2 to 272) was carried out as previously
described (59). Transcriptional reporters were constructed by PCR amplification
of vfr, exoS, or cpdA promoter fragments from P. aeruginosa (strain PAK)
genomic DNA using primers containing EcoRI and BamHI restriction sites. The
fragments correspond to the following promoter regions in bp relative to the
translational start codon: 310 to 60 for vfr, 553 to 78 for exoS, and 500
to  100 cpdA; fragment were digested with EcoRI and BamHI and cloned into
the same sites of plasmid mini-CTX-lacZ (19, 44). The resulting plasmids were
used to integrate the promoter-lacZ fusions onto the chromosome at the CTX
phage attachment site of wild-type and mutant P. aeruginosa strains as described
previously (19).
For CpdA expression in E. coli strain M15(pREP4) (Qiagen), cpdA (4
to 819 bp relative to translational start) was PCR amplified from P. aeruginosa
strain PAK genomic DNA using primers containing SphI and HindIII restriction
sites. The resulting product was cloned into the SphI-HindIII sites of pQE30
(Qiagen) to create pQE30-cpdA such that expression results in the production of
an amino-terminal His6-tagged version of full-length CpdA (His6-CpdA). Site-
directed mutagenesis of pQE30-cpdA was performed to generate His6-CpdA
amino acid substitution mutations [H23A, D63A, and N93A, yielding His6-
CpdA(H23A), His6-CpdA(D63A), and His6-CpdA(N93A), respectively] accord-
ing to the manufacturer’s protocol (Stratagene QuikChange II XL site-directed
mutagenesis kit).
To create P. aeruginosa gene expression plasmids, cpdA was PCR amplified
from P. aeruginosa strain PAK and E. coli strain DH1 genomic DNA and cloned
into pMMBV1GW (encoding pCpdA) or pMMBGW (encoding pEcCpdA),
respectively, using Gateway cloning (Invitrogen) as described previously (59).
For expression of His6-CpdA or mutant variants in P. aeruginosa, pQE30-cpdA
and its derivatives were digested with EcoRI and HindIII, and the cpdA-
containing fragments were cloned into the EcoRI and HindIII sites of
pMMBV2GW. The P. aeruginosa expression plasmid pMMBV1GW is a version
of the previously described vector pMMBGW (59) in which the sequence of the
35 region of the tac promoter was changed from TTGACA to TTTACA.
pMMBV2GW contains the alteration to the 35 region described above and an
additional modification of the 10 region, changing TATAAT to CATTAT (S.
Lory, unpublished data). These promoter region modifications reduce the effi-
ciency of transcriptional initiation at the tac promoter, allowing for reduced
levels of expression (data not shown).
For plasmid expression of vfr, the corresponding coding sequence was PCR
amplified from genomic DNA of P. aeruginosa strain PA103 using primers
incorporating NdeI and SacI restriction sites, and the resulting product was
cloned into the NdeI and SacI sites of the arabinose-inducible expression vector
pUY30 (54), resulting in plasmid p2UY22.
Protein purification. For His6-CpdA purification, an overnight culture of E.
coli strain M15(pREP4) (Qiagen) expressing wild-type P. aeruginosa cpdA or
mutant derivatives was diluted 1:100 in 500 ml of LB medium containing Cb (30
g/ml) and kanamycin (Kn; 25 g/ml). Cultures were grown with shaking at
37°C. When the OD600 reached 1.0, 500 M isopropyl -D-1-thiogalactopyrano-
side (IPTG) was added, and cultures were grown for 1 additional hour. Bacteria
were collected by centrifugation (10,000  g for 15 min at 4°C), and pellets were
stored at 80°C. Cell lysates were prepared as described previously (38) with the
exception that a protease inhibitor cocktail (Sigma) and 20 mM imidazole were
included in the lysis buffer. His6-tagged CpdA was isolated under native condi-
tions using Ni-nitrilotriacetic acid (NTA) agarose (Qiagen) according to the
manufacturer’s protocol (38) except that the buffer consisted of 50 mM
NaH2PO4 (pH 7.0), 300 mM NaCl, 80 mM imidazole, 2 mM MgCl2, 20 mM
-mercaptoethanol, 30% glycerol, and 0.1% Tween. Protein was desalted into 50
mM NaH2PO4 (pH 7.0), 300 mM NaCl, and 10% glycerol using a HiTrap
desalting column (GE Healthcare) and stored at 20°C.
For Vfr purification, P. aeruginosa strain PA103 exsA:: carrying p2UY22 was
grown overnight at 37°C on Vogel-Bonner minimal (VBM) medium (55) con-
taining gentamicin (Gm; 100 g/ml). Bacteria were inoculated into 100 ml of LB
medium containing 100 g/ml Gm and grown at 37°C with shaking. When an
OD600 of 0.3 was reached, arabinose was added to 0.4% to induce Vfr expression.
Following an additional 4.5-h incubation, bacteria were harvested by centrifuga-
tion (5,000  g for 5 min at 4°C), suspended in 2 ml of Vfr buffer (50 mM
Tris-HCl [pH 7.0], 100 mM KCl, 50 mM NaCl, 2 mM dithiothreitol [DTT], 2 mM
EDTA, 10% glycerol, 0.5% Tween-20) and lysed by sonication in an ethanol-ice
bath. Lysates were centrifuged (16,000  g for 5 min at 4°C) to remove unbroken
cells and then again at 100,000  g for 60 min to remove insoluble material. The
soluble material was applied to a 1-ml cAMP-agarose (Sigma) column and
washed with 15 ml of Vfr buffer, and protein was eluted with Vfr buffer contain-
ing 5 mM cAMP. The eluted protein was dialyzed against Vfr buffer and stored
at 80°C.
Size exclusion chromatography. Size exclusion chromatography of purified
CpdA was performed on a Sephacryl S-200 high-resolution column (GE Health-
care) attached to an ÄKTAxpress system (GE Healthcare) using 50 mM
NaH2PO4 (pH 6.8), 300 mM NaCl. A 1-ml aliquot of 10 M CpdA was loaded
onto the column at a flow rate of 1.2 ml/min. The size exclusion elution profile
of CpdA was compared to profiles of the following protein standards to deter-
mine the oligomeric state: thyroglobulin (670 kDa), gamma-globulin (158 kDa),
ovalbumin (44 kDa), myoglobin (17 kDa), and vitamin B12 (1.35 kDa).
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Phosphodiesterase activity assay. Using a PDELight HTS cAMP phospho-
diesterase kit (Lonza Rockland, Inc.), reaction mixtures (40 l total volume)
containing various concentrations of cAMP (0 to 20 M), purified CpdA (2 ng),
and reaction buffer (50 mM Tris-HCl [pH 7.6], 0.1 mM DTT) were incubated for
30 min at 25°C and then terminated. As indicated below and in the figure
legends, reaction mixtures contained ferrous chloride (10 M or 1 mM) and/or
CpdA that was previously incubated with 100 M 	-	-dipyridyl (Sigma) for 2 h
at 4°C. In this assay, the 5-AMP product formed during the reaction was
quantified by a bioluminescent readout that was measured using a Veritas mi-
croplate luminometer. A standard curve in which the amount of bioluminescence
produced from concentrations (0 to 0.2 M) of pure 5-AMP (Sigma) was used
to calculate CpdA activity (nM 5-AMP produced/min/ng of CpdA). Cyclic GMP
(cGMP) phosphodiesterase activity for CpdA was measured using a PDEGlo
phosphodiesterase assay (Promega) as described in the legend of Fig. S2 in the
supplemental material.
Intracellular cyclic nucleotide concentration measurements. Overnight cul-
tures of wild-type and mutant P. aeruginosa strains were diluted 1:100 into LB
medium. For plasmid-carrying strains, LB medium was supplemented with Cb
(30 g/ml) and IPTG (50 M). When cultures reached an OD600 of 3.0, 2-ml
aliquots of cells were collected by centrifugation (13,200  g for 3 min) and
washed twice with charcoal-treated phosphate-buffered saline (PBS; pH 7.0)
containing 1% Bacto Protease Peptone (BD). Half of each sample was resus-
pended in charcoal-treated 0.1 N hydrochloric acid (100 l), vortexed five times
during a 15-min incubation on ice, and centrifuged (13,200  g for 5 min). The
supernatant was used for cAMP (or cGMP) determination using an immunoas-
say (Cyclic AMP EIA kit or Cyclic GMP EIA kit; Cayman Chemical Co.)
TABLE 1. Strains and plasmids used in this work
Strain or plasmid Description or relevant characteristic(s)a Reference orsource
E. coli strains
M15(pREP4) Expression strain for pQE30-encoded proteins; Knr Qiagen
DH1 Cloning strain 18
P. aeruginosa strains
PAK Wild-type strain 53
PAK cyaA Nonpolar cyaA deletion in PAK 59
PAK cyaB Nonpolar cyaB deletion in PAK 59
PAK cyaA cyaB Nonpolar cyaA cyaB deletions in PAK 59
PAK vfr Nonpolar vfr deletion in PAK 59
PAK cpdA Nonpolar cpdA deletion in PAK This study
PAK cyaA cpdA Nonpolar cyaA cpdA deletions in PAK This study
PAK cyaB cpdA Nonpolar cyaB cpdA deletions in PAK This study
PAK cyaA cyaB cpdA Nonpolar cyaA cyaB cpdA deletions in PAK This study
PAK vfr cpdA Nonpolar cpdA vfr deletions in PAK This study
PA14 Wild-type strain 39
PA14 cpdA Nonpolar cpdA deletion in PA14 This study
PA103 Wild-type strain 28
PA103 cpdA Nonpolar cpdA deletion in PA103 This study
PA103 exsA::  element inactivation of exsA 14
PAO1 Wild-type strain 20
PAO1 cpdA Nonpolar cpdA deletion in PAO1 This study
Plasmids
pQE30 Plasmid for expressing His6-tagged proteins; Ap
r Qiagen
pQE30-cpdA cpdA (4 to 819 bases relative to translational start site) in SphI and HindIII
sites of pQE30
This study
pQE30-cpdA-H23A Same as pQE30-cpdA but with cpdA(H23A) This study
pQE30-cpdA-D63A Same as pQE30-cpdA but with cpdA(D63A) This study
pQE30-cpdA-N93A Same as pQE30-cpdA but with cpdA(N93A) This study
pMMB67EH Empty P. aeruginosa expression vector; Apr 16
pMMBGW Gateway-adapted version of pMMB67EH; Apr 59
pMMBV1GW pMMBGW with altered 35 sequence; Apr This study
pMMBV2GW pMMBV1GW with altered 10 sequence; Apr This study
pCpdA P. aeruginosa cpdA encoded by pMMBV1GW This study
pHis6CpdA EcoRI-HindIII fragment of pQE30-cpdA cloned into same sites of pMMBV2GW
for expression of His6-CpdA
This study
pHis6CpdA-H23A Same as pHis6CpdA but for expression of His6-CpdA(H23A) This study
pHis6CpdA-D63A Same as pHis6CpdA but for expression of His6-CpdA(D63A) This study
pHis6CpdA-N93A Same as pHis6CpdA but for expression of His6-CpdA(N93A) This study
pEcCpdA E. coli cpdA encoded by pMMBGW This study
pUY30 Arabinose-inducible expression vector; Gmr 54
p2UY22 vfr coding sequence in NdeI and SacI sites of pUY30 Yahr laboratory
mini-CTX-lacZ Plasmid for chromosomal integration of promoter-lacZ transcriptional fusions; Tcr 19, 44
mini-CTX-Pvfr-lacZ vfr promoter region (310 bp to 60 bp relative to translational start) in EcoRI
and BamHI sites of mini-CTX-lacZ
This study
mini-CTX-PexoS-lacZ exoS promoter region (553 bp to 78 bp relative to translational start) in EcoRI
and BamHI sites of mini-CTX-lacZ
This study
mini-CTX-PcpdA-lacZ cpdA promoter region (500 bp to 100 bp relative to translational start) in
EcoRI and BamHI sites of mini-CTX-lacZ
This study
a Apr, ampicillin resistance; Knr, kanamycin resistance; Gmr, gentamicin resistance; Tcr, tetracycline resistance.
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following the acetylation protocol. The remaining sample was resuspended in
PBS (100 l), subjected to three freeze-thaw cycles, and centrifuged (13,200  g
for 3 min), and the supernatant was used for total protein determination (bicin-
choninic acid [BCA] protein assay; Thermo Scientific). Assay results were used
to calculate the intracellular cAMP (or cGMP) concentration based on the
estimated cellular volume for P. aeruginosa per mg of protein (4.92 l/mg of total
cellular protein) (11). As indicated above, reagents were mixed with charcoal (10
g per liter) for 30 min to remove cyclic nucleotide contaminants and then filter
sterilized.
-Galactosidase assays. Overnight cultures of strains containing vfr, exoS, and
cpdA promoter-lacZ fusions were diluted 1:100 to 1:200 into LB medium and
grown to mid-log phase (OD600 of 1.0). Cb (30 g/ml), IPTG (50 M), EGTA
(5 mM), and MgCl2 (5 mM) were added to the medium as indicated in the figure
legends. Levels of -galactosidase were measured as described previously (31).
Each assay was repeated at least three times.
Western blotting. For detection of Vfr protein, overnight cultures were diluted
1:200 into LB medium and grown to mid-log phase (OD600 of 1.0). Culture
aliquots (1 ml) were centrifuged (13,200  g for 3 min), and cell pellets were
resuspended in 100 l of PBS (pH 7.0) and subjected to three freeze-thaw cycles.
After centrifugation (13,200  g for 3 min), the protein concentration of the
supernatant was determined (BCA protein assay). Samples were normalized for
total protein, diluted in SDS loading buffer, boiled for 1 min, and loaded onto a
12% SDS-polyacrylamide gel for electrophoresis. Proteins were transferred to a
nitrocellulose membrane, and Vfr was detected using anti-Vfr rabbit serum
(1:25,000 dilution) and horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (1:25,000 dilution; Rockland). Blots were developed with Immobilon
Western chemiluminescence reagents (Millipore) and visualized by autoradiog-
raphy. Detection of His6-CpdA and mutant derivatives was carried out as de-
scribed above except that overnight cultures were diluted 1:100 into LB medium
containing Cb (30 g/ml) and IPTG (50 M) and were grown to an OD600 of 3.0.
Anti-His tag monoclonal antibody (1:10,000 dilution; Millipore) and HRP-con-
jugated anti-mouse IgG (1:10,000 dilution; Jackson) were used as primary and
secondary antibodies, respectively.
For detection of secreted ExoS protein, overnight cultures were diluted 1:100
into LB medium containing 5 mM EGTA and 5 mM MgCl2 and grown to an
OD600 of 
1.0. For detection of secreted ToxA, overnight cultures were diluted
1:100 into deferrated Bacto tryptic soy broth (BD) (36) and grown to an OD600
of 
2.0. Aliquots of culture supernatants (1 ml) were subjected to precipitation
by trichloroacetic acid (75 l) for 1 h on ice, centrifuged (13,200  g for 15 min
at 4°C), and washed with acetone (1 ml) overnight at 4°C. Protein pellets were
dried and resuspended in 50 l of PBS. Samples were normalized and analyzed
by Western blotting as described above using anti-ExoS rabbit serum (1:3,000
dilution), anti-Pseudomonas exotoxin A (ToxA) rabbit serum (1:100,000 dilution;
Sigma), and HRP-conjugated goat anti-rabbit IgG (1:25,000 dilution for ExoS;
1:100,000 dilution for ToxA; Rockland). All Western blotting experiments were
repeated a minimum of three times with independently derived protein samples,
and representative blots are shown.
Protease IV assay. Overnight cultures were diluted 1:100 into LB medium and
grown to early stationary phase (OD600 of 4.0). Bacteria were pelleted by cen-
trifugation (13,200  g for 3 min), and supernatants were concentrated 40
using Vivaspin 2 spin filters (molecular-weight-cutoff [MWCO] of 10 kDa; Sar-
torius Stedium Biotech) and assayed for total protein content (BCA protein
assay). Protease IV activity was determined as described previously (35) with the
exception that 50 mM Tris-HCl (pH 7.6)–0.1 M NaCl was used as the reaction
buffer, and the absorbance at 410 nm was measured at 10-min intervals for 1 h
upon addition of the substrate N-(p-tosyl)-Gly-Pro-Lys-4-nitroanilide (Chro-
mozym PL; Roche) to the reaction mixture. Protease IV activity was calculated
as the change in absorbance at 410 nm over time, divided by the protein con-
centration of concentrated culture supernatant.
EMSAs. DNA probes were generated by PCR and end labeled using 10 Ci of
[-32P]ATP (GE Healthcare) and 10 U of T4 polynucleotide kinase (New En-
gland Biolabs). Electrophoretic mobility shift assays (EMSAs) were performed
as previously described (8). Briefly, probes (0.25 nM each) were incubated in
binding buffer (10 mM Tris [pH 7.5], 50 mM KCl, 1 mM EDTA, 1 mM DTT, 5%
glycerol and 100 g/ml bovine serum albumin) containing 5 g/ml poly(2-
deoxyinosinic-2-deoxycytidylic acid) (Sigma) for 5 min at 25°C. Purified Vfr
protein was added to the concentration indicated in the figure legends for a final
reaction volume of 20 l, and the mixture was incubated for an additional 15 min
at 25°C. Samples were subjected to electrophoresis on a 5% polyacrylamide
glycine gel (10 mM Tris [pH 7.5], 380 mM glycine, 1 mM EDTA) at 4°C. Imaging
and data analyses were performed using an FLA-7000 phosphorimager (Fujifilm)
and MultiGauge, version 3.0, software (Fujifilm).
DNase I footprinting assays. Single end-labeled -32P double-stranded DNA
probes were generated by PCR in which one oligonucleotide primer was modi-
fied (5 Amino-MC6; Integrated DNA Technologies) at the 5 end to prevent
phosphorylation. Probes were subsequently labeled as described above. Foot-
printing reaction mixtures consisted of end-labeled probe (10 fmol) with 5 g/ml
poly(2-deoxyinosinic-2-deoxycytidylic acid) (Sigma) in DNase I reaction buffer
(10 mM Tris [pH 8.0], 50 mM KCl, 2 mM MgCl2, 0.5 mM DTT, 100 g/ml bovine
serum albumin, 10% glycerol). Purified Vfr was added for a final reaction
volume of 25 l, and the mixture was incubated for 15 min at 25°C. DNase I
footprinting and DNA sequencing reactions were performed as previously
described (30, 43, 50).
Statistical analysis. A two-tailed unpaired t test was used for data comparison
where appropriate. Statistical calculations and estimation of enzyme kinetic
parameters were preformed using Prism software, version 5.0b (GraphPad Soft-
ware).
Identification, cloning, and sequencing the cpdA gene of P. aeruginosa strain
PAK. The cpdA gene (locus PA4969) was identified upon searching the Pseudo-
monas Genome Database (58) for genes homologous to E. coli cpdA (21, 33).
Sequence corresponding to the cpdA open reading frame was PCR amplified
from genomic DNA of P. aeruginosa strain PAK using primers designed from the
P. aeruginosa strain PAO1 genomic sequence (58). The DNA fragment was
cloned into pMMBV1GW as described previously (59), and both DNA strands
were sequenced (Eurofins MWG Operon); specific primer sequences are avail-
able upon request. The PAK cpdA nucleotide sequence (which contains nucle-
otide differences compared to the PAO1 cpdA sequence) was assembled with
Sequencher, version 4.8, software.
Nucleotide sequence accession number. The P. aeruginosa PAK cpdA (PA4969)
nucleotide sequence was deposited in the GenBank sequence data library under the
accession number GU551724.
RESULTS
P. aeruginosa CpdA exhibits cAMP phosphodiesterase activ-
ity in vitro. To identify and characterize the enzyme(s) respon-
sible for cAMP degradation in P. aeruginosa, we searched the
Pseudomonas Genome Database (58) for genes whose prod-
ucts were homologous to members of the class I, II, and III
families of cAMP phosphodiesterases. We found a single gene
(PA4969) whose predicted product shares 41% identity with E.
coli CpdA (21) and 21% identity with a previously character-
ized cyclic nucleotide phosphodiesterase of M. tuberculosis
(Rv0805) (46) (Fig. 1A). Like E. coli CpdA and Rv0805, the P.
aeruginosa protein contains the highly conserved sequence mo-
tif D-(X)n-GD-(X)n-GNH(E/D)-(X)n-H-(X)n-GHXH (where
X is any residue, and n is the number of repeats) that is
characteristic of known class III cyclic nucleotide phospho-
diesterases, purple acid phosphatases, and other dimetallophos-
phoesterases (41). Thus, based on primary sequence analysis,
we have designated the PA4969 gene product CpdA.
To determine whether P. aeruginosa CpdA possessed phos-
phodiesterase activity, a full-length amino-terminal hexahisti-
dine-tagged version of CpdA was purified under nondenatur-
ing conditions (see Fig. S1 in the supplemental material). Size
exclusion chromatography revealed that CpdA had an elution
profile representative of an 
31-kDa protein, indicating that
CpdA (which has a predicted molecular mass of 30 kDa) is
monomeric in solution (data not shown). Cyclic AMP phos-
phodiesterase activity was determined in vitro by measuring
the amount of 5-AMP produced at various concentrations of
cAMP substrate (0 to 20 M) with a constant amount of CpdA
(2 ng) protein. In the presence of CpdA, 5-AMP was pro-
duced in a linear fashion with increasing cAMP concentrations
up to 
8 M (Fig. 1B). In contrast, there was no detectable
increase in 5-AMP when CpdA was not included in the reac-
tion mixture (data not shown). These results demonstrate that
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P. aeruginosa CpdA is, in fact, a cAMP phosphodiesterase with
an estimated Km of 7.2  1.4 M cAMP and Vmax of 3.4  0.3
nM 5-AMP produced/min/ng of enzyme. While a proven bi-
ological role for 3,5-cyclic GMP (cGMP) in bacteria remains
to be determined (26), some class III cyclic nucleotide phos-
phodiesterases can use both cAMP and cGMP as substrates in
vitro (6, 15, 46). We observed that CpdA of P. aeruginosa also
exhibited cGMP phosphodiesterase activity in vitro (see Fig.
S2); however, enzyme kinetics could not be determined by the
assay method employed, and this activity was not pursued
further due to our inability to detect the presence of cGMP in
P. aeruginosa strains (see below).
Iron and conserved residues are essential for CpdA activity.
In purple acid phosphatases and other dimetallopho-
sphoesterases, residues within the conserved sequence motif
D-(X)n-GD-(X)n-GNH(E/D)-(X)n-H-(X)n-GHXH coordi-
nate a Fe3-Me2 center (where Me2 can be Fe2, Zn2, or
Mn2) that is required for enzyme activity (41). Since CpdA
shares this sequence motif, we examined the metal ion require-
ment for CpdA activity. Similar to previous in vitro studies of E.
coli CpdA (21, 33), addition of 10 M ferrous chloride, as a
source of Fe2, resulted in an 
2-fold stimulation of P. aerugi-
nosa CpdA activity (Fig. 1B). The addition of ferrous chloride
did not significantly influence substrate affinity (Km of 6.7  1.2
M cAMP) but did increase the rate of the 5-AMP produc-
tion (Vmax of 5.6  0.4 nM 5-AMP produced/min/ng of en-
zyme). The addition of other divalent metals (Mg2, Mn2,
Zn2, and Ca2) had no effect (data not shown). Furthermore,
treatment of CpdA with the Fe2-specific chelator 	-	-dipyri-
dyl resulted in a nearly complete loss of activity (Fig. 1B);
addition of ferrous chloride (1 mM) to the 	-	-dipyridyl-
treated CpdA fully restored cAMP phosphodiesterase activity
(data not shown). These results suggest that the catalytic mech-
anism for P. aeruginosa CpdA utilizes a Fe3-Fe2 center.
To further investigate which residues within the D-(X)n-
GD-(X)n-GNH(E/D)-(X)n-H-(X)n-GHXH motif likely partic-
ipate in the binding of iron, we constructed a homology model
FIG. 1. P. aeruginosa CpdA is homologous to class III cAMP phos-
phodiesterases and degrades cAMP in vitro. (A) Protein sequence
alignment between the cpdA gene product from P. aeruginosa (strain
PAK) and the cAMP phosphodiesterase enzymes of E. coli (CpdA)
and M. tuberculosis (Rv0805). P. aeruginosa (P.a.) CpdA shares 41%
and 21% identity with the homologous enzymes of E. coli (E.c.) and M.
tuberculosis (M.t.), respectively. Amino acid residue numbers are given
in brackets. Symbols indicate identical (*), conserved (:), or semicon-
served (.) amino acids as determined by Clustal W2 software (25).
Residues conserved among all class III cyclic nucleotide phosphodies-
terases (41) are indicated in bold type. Arrows mark the amino acids
of P. aeruginosa CpdA that were mutated to alanine in this study. The
P. aeruginosa CpdA protein sequence was derived from strain PAK
cpdA (PA4969) nucleotide sequence data that have been deposited in
GenBank under the accession number GU551724. (B) The rate of
5-AMP production (nM 5-AMP produced/min/ng CpdA) was deter-
mined after incubating purified CpdA protein (2 ng) with increasing
concentrations of cAMP substrate (0 to 20 M) for 30 min at 25°C.
The assay was carried out with CpdA (as purified, CpdA plus 10 M
ferrous chloride, or CpdA that was first incubated with 100 M 	-	-
dipyridyl for 2 h at 4°C. The rate of 5-AMP production for the
active-site mutant CpdA(H23A) is also shown; activities of the mutant
proteins CpdA(D63A) and CpdA(N93A) (data not shown) were sim-
ilar to activity of CpdA(H23A). Values represent the mean  standard
error of the mean of at least three independent assays. (C) Structural
model of the P. aeruginosa CpdA active site. The Protein homology/
analogy recognition engine (Phyre) (23) was used to align the P.
aeruginosa strain PAK CpdA protein sequence with the solved struc-
ture of the cyclic nucleotide phosphodiesterase of M. tuberculosis
(Rv0805). In the crystal structure of Rv0805 (Protein Data Bank ac-
cession code 2HYP), the highlighted conserved amino acid residues
were shown to coordinate a Fe3-Mn2 center (45).
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of CpdA based on the solved crystal structure of Rv0805 (45)
(Fig. 1C). This model reveals that the highly conserved amino
acids D21, H23, D63, N93, H162, H200, and H202 (Fig. 1A)
cluster together in the three-dimensional protein structure
(Fig. 1C), suggesting that they may form the Fe3-Fe2 bind-
ing site. To address the significance of these conserved residues
in P. aeruginosa CpdA function, alanine substitutions of three
different CpdA amino acids (H23, D63, and N93) were con-
structed. The resulting mutant proteins were purified and
tested for cAMP phosphodiesterase activity in vitro. Unlike the
wild-type CpdA, there was no detectable activity (0.1% of
wild-type CpdA) for any of the mutant proteins [data for
CpdA(H23A) are shown in Fig. 1B]. In addition, the mutant
proteins had no detectable activity when assayed in the pres-
ence of 10 M ferrous chloride (data not shown). Taken to-
gether, these results indicate that the highly conserved residues
H23, D63, and N93 are essential for CpdA activity and are
consistent with their proposed role in coordinating iron ions
within the active site.
CpdA affects the levels of intracellular cAMP. To determine
if CpdA plays a role in regulating cAMP levels in vivo, the
intracellular cAMP concentration was determined for wild-
type P. aeruginosa strain PAK and an isogenic mutant in which
the cpdA gene was deleted. The cpdA mutant contained nearly
30-fold higher cellular cAMP levels than the wild-type strain
(Fig. 2A), suggesting that the cpdA gene product participates
in decreasing the cAMP concentration in vivo. Introduction of
the cpdA deletion into other commonly studied P. aeruginosa
strains (PA14, PA103, and PAO1) also resulted in a dramatic
increase in intracellular cAMP (see Fig. S3A in the supple-
mental material), indicating that CpdA function is conserved
among P. aeruginosa strains. The cellular cAMP concentration
in the cpdA mutant could be reduced upon plasmid-based
expression of either P. aeruginosa cpdA or E. coli cpdA (Fig.
2B), demonstrating that the mutant phenotype was specifically
due to deletion of cpdA. In addition, plasmid-encoded His6-
CpdA also complemented the cpdA mutant, indicating that
His6-CpdA is functional in vivo (Fig. 2B). In contrast, when
expressed to an equivalent level, the putative active-site mutants
of His6-CpdA were unable to complement the cpdA mutant (Fig.
2B). Thus, these results correlate with those observed in the in
vitro assay and further demonstrate that the conserved residues
H23, D63, and N93 are required for CpdA activity.
To evaluate the balance of cAMP synthesis and degradation,
we also determined the effect of the cpdA deletion on cAMP
levels in mutants lacking the endogenous adenylate cyclases
(ACs) CyaA and CyaB. As previously observed (59), cellular
cAMP levels were slightly lower in a cyaA mutant and reduced
by 
50% in a cyaB mutant relative to the wild type (Fig. 2A).
These results are consistent with the notion that in P. aerugi-
nosa, the contribution of CyaB to the cAMP pool is substan-
tially greater than that of CyaA. Upon deletion of cpdA, cAMP
levels increased 25-fold in the cyaA mutant. Deletion of cpdA
in the cyaB mutant strain resulted in a 9.5-fold increase in
intracellular cAMP. These results indicate that in wild-type P.
aeruginosa, CpdA and CyaB are the major enzymes responsible
for controlling cellular cAMP concentration. Cyclic AMP lev-
els were 
3-fold higher in the cyaA cyaB cpdA triple mutant
than in the cyaA cyaB double mutant even though both strains
lack the two known P. aeruginosa ACs responsible for cAMP
synthesis. P. aeruginosa, like other Gram-negative bacteria, is
capable of acquiring extracellular cAMP by an unknown trans-
port mechanism (7, 15a, 42). Since contaminating cAMP was
not removed from the bacterial growth medium (LB), its up-
FIG. 2. Deletion of cpdA results in increased cellular cAMP. Bacterial
cultures were grown in LB medium to an OD600 of 3.0. Plasmid-contain-
ing strains were grown in the presence of Cb (30 g/ml) and IPTG (50
M). The concentration of cAMP was measured by immunoassay (Cay-
man Chemical Co.). Data represent at least three independent assays, and
values are reported as the mean  standard error of the mean. (A) In-
tracellular cAMP levels for wild-type (WT) P. aeruginosa strain PAK, the
cyaA, cyaB, and cyaA cyaB (cyaAB) mutants (gray bars), and the respec-
tive isogenic cpdA (black bars) strains. Numbers above each bar indicate
the mean intracellular cAMP concentration (M). The values for all cpdA
mutants were significantly different (P  0.005) in pairwise comparisons
to the values for their corresponding isogenic cpdA parent strains.
(B) Intracellular cAMP levels for WT and cpdA strains carrying an empty
vector or plasmid-encoded wild-type CpdA from P. aeruginosa (pCpdA)
or E. coli (pEcCpdA), His6-CpdA, or the indicated His6-CpdA alanine
substitution mutants. The asterisk indicates that the values for the indi-
cated strains were significantly different (P  0.001) in pairwise compar-
isons the values for the cpdA mutant carrying the empty vector. A West-
ern blot of normalized bacterial lysates probed with anti-His6 antibody is
shown in the inset.
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take may account for the elevated level detected in the triple
mutant. However, low activity associated with a previously
unidentified AC cannot be ruled out.
To determine whether CpdA also affects intracellular cGMP
levels in P. aeruginosa, we measured the cGMP content in
wild-type and cpdA mutant versions of strains PAK, PA14,
PA103, and PAO1. In all cases, the intracellular level of cGMP
was below the limit of detection (0.01 M) (data not shown),
suggesting that cGMP is unlikely to be synthesized by P. aerugi-
nosa and that cAMP is the biologically relevant substrate for
CpdA in vivo.
CpdA affects vfr expression and Vfr protein levels. We have
recently shown that the cAMP-Vfr complex, in addition to
regulating hundreds of genes involved in virulence (59), di-
rectly controls vfr promoter activation (E. L. Fuchs et al.,
submitted for publication). Thus, vfr gene expression is auto-
regulated and cAMP dependent. To first address how viru-
lence gene expression is affected by elevated intracellular
cAMP levels, we determined if vfr promoter activity was al-
tered in the cpdA mutant by measuring -galactosidase activity
in strains containing a chromosomal copy of the vfr promoter-
lacZ fusion. In the cpdA mutant, vfr promoter activity was

12-fold higher than in the parental wild-type strain (Fig. 3A).
Similar increases were observed in cpdA mutants that lacked
cyaA, cyaB, or both AC genes. Plasmid-based expression of
either P. aeruginosa cpdA or E. coli cpdA restored vfr promoter
activity in the cpdA mutant to the level observed for the wild-
type strain (Fig. 3C). Thus, increased concentrations of cAMP
resulted in elevated vfr gene expression. Consistent with this
result, Western blot analysis revealed that Vfr protein levels
were substantially higher in cpdA mutant strains than in the
respective parent strains (Fig. 3B). Taken together, these data
suggest that elimination of cpdA results in elevated levels of
the cAMP-Vfr complex.
CpdA affects production of virulence factors ExoS, ToxA,
and protease IV. Given that CpdA plays a role in controlling
intracellular cAMP-Vfr levels, we examined the effect of the
cpdA deletion on virulence factor production. ExoS is a toxic
effector protein secreted by the T3SS directly into host cells
(12). Expression of the T3SS and its effector-encoding genes is
regulated by cAMP-Vfr; however, the mechanism of regulation
is currently unknown (59, 60). To measure expression of exoS,
we created a transcriptional reporter by fusing the exoS pro-
moter region to the lacZ gene and introduced the fusion in
single copy onto the chromosome of wild-type and mutant
strains. -Galactosidase assays revealed that with exception of
the vfr mutant, exoS promoter activity was significantly higher
in all cpdA mutants than in the respective cpdA parent strains
(Fig. 4A). In addition, Western blot analysis showed that the
amount of secreted ExoS protein was higher for the cpdA
mutants (Fig. 4B). Thus, transcription of exoS and secretion of
its gene product are increased in response to elevated levels of
cAMP-Vfr.
Similar trends were observed for two additional secreted
virulence factors: ToxA (an ADP-ribosyltransferase) and pro-
tease IV. Unlike ExoS, ToxA and protease IV are secreted by
a type II secretion system. Previous studies have shown that
Vfr is required for the production and secretion of ToxA and
protease IV and that cAMP-Vfr directly binds the promoter
region of their respective genes, toxA and prpL (piv) (22, 56).
Western blot analysis revealed that the level of ToxA in bac-
terial culture supernatants was higher in mutant strains lacking
cpdA (Fig. 4C). Protease IV secretion was examined indirectly
by measuring protease IV-dependent proteolysis of the chro-
mogenic substrate N-(p-tosyl)-Gly-Pro-Lys-4-nitroanilide. Pro-
tease IV activity was elevated 
 2-fold in culture supernatants
derived from the cpdA and cyaA cpdA mutant strains com-
FIG. 3. vfr promoter activity and Vfr protein levels are elevated in
a cpdA mutant. (A) vfr promoter activity measured as -galactosidase
activity (Miller units) from the vfr-lacZ promoter reporter in the wild-
type (WT), cyaA, cyaB, cyaA cyaB (cyaAB), and vfr strains and the
isogenic cpdA mutants. Results are presented as mean  standard
error of the mean for four independent experiments. The asterisk
signifies that the values for the indicated cpdA mutants were signifi-
cantly different (P  0.0001) in pairwise comparisons to the values for
the corresponding isogenic cpdA strains. (B) Western blot of whole-
cell lysates normalized for total protein and probed with Vfr-specific
antiserum. (C) -Galactosidase activity from the vfr-lacZ promoter
reporter in WT and cpdA mutant strains containing empty vector or
the same vector encoding either P. aeruginosa CpdA (pCpdA) or E.
coli CpdA (pEcCpdA). Cultures were grown in LB medium containing
Cb (30 g/ml) and IPTG (50 M). Results are presented as mean 
standard error of the mean and represent three independent experi-
ments. The asterisk indicates that the value for the cpdA mutant with
empty vector was significantly different (P  0.0001) in a pairwise
comparison to the values for all other strains.
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pared to wild-type and cyaA strains, respectively (Fig. 4D).
Consistent with this observation, the cpdA mutant produced a
larger zone of proteolytic clearing than the wild type on low-
salt LB agar containing 1.5% milk (Fig. 4D). Taken together,
these results indicate that CpdA plays a role in maintaining an
intracellular cAMP level that is most likely optimized for ap-
propriate virulence factor expression.
The cpdA mutant has a cAMP-independent small-colony,
slow-growth phenotype. In other bacterial species, deletion of
genes encoding CpdA homologs results in pleiotropic effects
on cell growth. For instance, cpdA mutants of Salmonella en-
terica serovar Typhimurium have increased antibiotic sensitiv-
ities and faster growth in the presence of certain carbon
sources than their parent strains (2). In addition, it was re-
cently reported that in Vibrio vulnificus, deletion of cpdA re-
sulted in an elongated cell morphology compared to a wild-
type strain (24). During the course of this study, we observed a
growth phenotype associated with the loss of cpdA in P. aerugi-
FIG. 4. Virulence factor production is upregulated in a cpdA mutant.
(A) exoS promoter activity was measured by assaying the amount of
-galactosidase activity (Miller units) produced from a single-copy chro-
mosomal exoS promoter-lacZ reporter gene in wild-type (WT), cyaA,
cyaB, cyaA cyaB (cyaAB), and vfr strains and the respective cpdA mutants.
Cultures were grown in LB medium containing 5 mM EGTA (low Ca2)
and 5 mM MgCl2 to induce the T3SS. Values represent the mean 
standard error of the mean of triplicate assays. The asterisk indicates that
the values for the indicated cpdA mutants were significantly different (P 
0.005) in pairwise comparisons to the values for the corresponding iso-
genic cpdA strains. (B) Western blot analysis of secreted ExoS protein in
concentrated culture supernatants normalized for total protein. Strains
were grown as described above. (C) Western blot analysis of secreted
ToxA in concentrated culture supernatants normalized for total protein.
Strains were grown in deferrated tryptic soy broth (low iron) to an OD600
of 2.0 to induce ToxA expression. (D) Protease IV activity from concen-
trated supernatants of cultures grown in LB medium to early stationary
phase (OD600 of 4.0). Samples were incubated with the protease IV-
specific, chromogenic substrate N-(p-tosyl)-Gly-Pro-Lys-4-nitroanilide for
1 h at 37°C. Protease IV activity was calculated as the change in absor-
bance at 410 nm/min/g of total protein. Values represent the mean 
standard error of the mean of at least three independent assays. The
asterisk indicates that the values for the indicated cpdA mutants were
significantly different (P  0.002) in pairwise comparisons to the values for
the corresponding isogenic cpdA strains. Inset shows caseinolytic pro-
tease activities for the WT and cpdA mutant strains. Five microliters of
overnight culture was spotted onto low-salt LB (5 mM NaCl) agar con-
taining 1.5% skim milk and incubated at 25°C for 24 h. The production
and secretion of protease IV result in the degradation of milk proteins,
creating a zone of clearing around the bacterial colony (52, 57).
FIG. 5. Deletion of cpdA results in a cAMP-independent altered
growth phenotype. (A) The doubling times of cpdA strains and iso-
genic cpdA mutants during exponential growth in LB broth. The cpdA
mutant, expressing plasmid-encoded P. aeruginosa CpdA (pCpdA) or
E. coli CpdA (pEcCpdA) was grown in the presence of Cb (30 g/ml)
and IPTG (50 M). Growth experiments were repeated a minimum of
three times. Values represent the mean  standard error of the mean.
Doubling times for the cpdA mutant strains were significantly different
(P  0.0001) in pairwise comparisons to the values for the correspond-
ing isogenic cpdA strains or plasmid-complemented strains. (B) Col-
ony phenotype of wild-type (WT) and cpdA mutant strains containing
empty vector, pCpdA, or pEcCpdA. Serial 10-fold dilutions of over-
night cultures were spotted (10 l) on LB agar containing Cb (150
g/ml) and IPTG (50 M) and grown for 16 h at 37°C prior to imaging.
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nosa. When grown in rich liquid medium (LB medium) (Fig.
5A), the cpdA mutant exhibited a significantly reduced growth
rate compared to that of the parental wild-type strain; the
doubling time for the cpdA mutant (51  6 min) was approx-
imately twice that of the wild type (28  5 min). The reduced
growth rate was specific for rich medium since the cpdA
mutant and wild-type strains had similar doubling times
when they were grown in a minimal defined medium con-
taining either 10 mM succinate (see Fig. S4A in the supple-
mental material) or 10 mM glucose (data not shown) as the
sole carbon source. In addition to the slow-growth pheno-
type in LB broth, the cpdA mutant also produced small
colonies on solid medium (LB agar) (Fig. 5B). The growth
rate and colony morphology could be restored in the cpdA
mutant when it was complemented with plasmid-expressed
P. aeruginosa cpdA or E. coli cpdA (Fig. 5).
To determine whether elevated intracellular cAMP levels
associated with the loss of cpdA accounted for the defect in cell
growth, we examined the contribution of the endogenous ACs
CyaA and CyaB. The doubling times for cpdA AC mutants
were similar to the doubling time of the wild type. However,
deletion of cpdA in the AC mutant strains resulted in signifi-
cantly slower growth in rich liquid medium (Fig. 5A) and the
formation of small colonies (data not shown). These results
indicate that increased cAMP is not responsible for the altered
growth phenotype and suggest that P. aeruginosa CpdA is likely
to have an additional function beyond its role in cAMP deg-
radation. Interestingly, the cpdA-specific small-colony pheno-
type could not be complemented with plasmids expressing the
active-site mutants CpdA(H23A), CpdA(D63A), and CpdA
(N93A) (see Fig. S4B in the supplemental material), indicating
that these conserved residues are required for wild-type
growth.
cpdA expression is positively regulated by cAMP-Vfr. As
shown in Fig. 2A, introduction of the cpdA deletion into wild-
type strain PAK and the isogenic cyaA and cyaB mutant strains
resulted in increased intracellular cAMP. However, the con-
tribution of CpdA in each background was disproportionate.
For example, cAMP levels in the cpdA mutant were nearly
30-fold higher than the level in the wild-type strain but only
9.5-fold higher in the cpdA cyaB double mutant than in the
cyaB mutant. This finding suggests that CpdA activity or ex-
pression may be downregulated in strains that synthesize less
cAMP. To further explore this possibility, we tested whether
cAMP-Vfr regulates cpdA expression. Specifically, we con-
structed a single-copy cpdA transcriptional reporter gene by
fusing the putative cpdA promoter region to a promoterless
lacZ gene at a vacant CTX phage integration site on the P.
aeruginosa chromosome. Expression of the cpdA promoter-
lacZ fusion in strains lacking the ACs, vfr, or cpdA was assessed
using -galactosidase assays. Compared to the wild-type strain,
-galactosidase activity decreased 
3- and 5-fold in the cyaA
cyaB double mutant and the vfr mutant, respectively. In con-
trast, activity increased 
2-fold in the cpdA mutant (Fig. 6A).
These results suggest that cpdA expression is regulated in re-
sponse to the cellular concentration of cAMP via the cAMP-
Vfr complex.
To determine if cAMP-Vfr directly regulates cpdA, an elec-
trophoretic mobility shift assay (EMSA) was performed with
purified cAMP-Vfr and three DNA probes, encompassing
different regions of the cpdA promoter (Fig. 6B). The mo-
bility of probe 3, corresponding to 231 bp to 1 bp relative
to the cpdA translational start codon, was specifically re-
tarded by the cAMP-Vfr complex in a concentration-depen-
dent manner. Furthermore, DNase I footprinting analysis
revealed that cAMP-Vfr altered the cleavage pattern of a
region within the cpdA promoter spanning from 112 bp to
76 bp relative to the cpdA translational start codon (Fig. 6C).
Specifically, cAMP-Vfr protected a 25-bp sequence (104 bp
to 80 bp) from DNase I cleavage with the exception of strong
hypersensitive sites at positions 86, 96, and 97. There was
also enhanced DNase I cleavage at positions 76 and 112 bp.
A similar pattern of DNase I hypersensitivity was observed
in footprints of the lasR, ptxR, toxA, and regA promoters in
the presence of cAMP-Vfr (1, 13, 22). Furthermore, 14 of
the bases (underlined) within the protected sequence of the
cpdA promoter (5-CAACTGTGATCT  GTTCCGCTT-3)
matched the reported consensus Vfr binding sequence (5-
ANWWTGNGAWNY  AGWTCACAT-3, where W is A
or T, Y is T or C, and N is any nucleotide) (22). Taken
together, these data reveal that cAMP-Vfr binds to the cpdA
promoter region, suggesting that in vivo, cpdA transcription
is directly activated by cAMP-Vfr.
DISCUSSION
We have provided definitive in vitro evidence that purified
CpdA of P. aeruginosa hydrolyzes the second messenger sig-
naling molecule cAMP to form biologically inactive 5-AMP
(Fig. 1B). Furthermore, the dramatic increase in intracellular
cAMP in cpdA mutant strains indicates that CpdA exhibits
cAMP phosphodiesterase activity in vivo (Fig. 2; see also Fig.
S3A in the supplemental material). While CpdA has features
in common with other class III cyclic nucleotide phosphodies-
terases, such as the metal ion requirement and conserved
amino acid residues, several substantial differences in the prop-
erties of these bacterial enzymes exist. For instance, the Km
calculated for P. aeruginosa CpdA (7.2  1.4 M for cAMP) is

6-fold lower than that of E. coli CpdA (
45 uM) (21, 33),
indicating that P. aeruginosa CpdA may exhibit a stronger
affinity for cAMP. In addition, while both of these enzymes
function as monomers, a previous study has shown that Rv0805
of M. tuberculosis functions as a dimer (46). Differences in
oligomeric state may account for alterations in binding of
cAMP and/or the metal ion cofactors and may explain why
alanine substitution of specific conserved active-site residues
had variable effects on Rv0805 activity (46) but completely
inactivated P. aeruginosa CpdA. Finally, in contrast to the
finding that E. coli CpdA does not degrade cGMP (21), we
observed that P. aeruginosa CpdA exhibited cGMP phospho-
diesterase activity in vitro (see Fig. S2), similar to Rv0805 (46)
and the CpdA enzyme from the cyanobacterium Anabaena sp.
strain PCC 7120 (15). While these enzymes appear to have
dual specificity like many class I mammalian cyclic nucleotide
phosphodiesterases (6), the relevance of cGMP degradation in
P. aeruginosa is unclear, given the lack of measurable cGMP
synthesis in vivo.
Although cAMP phosphodiesterases are ubiquitous in na-
ture, the global role these enzymes play in bacteria is not well
understood. In this study, we investigated how the cAMP phos-
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phodiesterase activity of CpdA contributes to cAMP signaling
in P. aeruginosa. Since the cAMP-Vfr complex affects the ex-
pression of 
200 genes, many of which are involved in viru-
lence (59), it is not surprising that cAMP levels are tightly
controlled. Our data reveal that CpdA plays a major role in
this process by reducing intracellular cAMP and, in turn, af-
fecting cAMP-Vfr-dependent virulence factor expression. We
propose that CpdA activity would be advantageous in the ab-
sence of a host in order to maintain basal cAMP levels. For
example, in the environment, CpdA activity would limit cAMP
accumulation, thus preventing the unnecessary expression of
virulence factors. Furthermore, in the context of infection,
CpdA activity may allow P. aeruginosa to reset the cAMP
signaling cascade following AC activation in response to spa-
tiotemporal signals present in the host. Studies have demon-
strated that inhibition of virulence factor production occurs
FIG. 6. Transcription of cpdA is directly activated by cAMP-Vfr. (A) cpdA promoter activity was determined by -galactosidase assay (Miller
units) in wild-type (WT), cyaA, cyaB, cyaA cyaB (cyaAB), and vfr strains (gray bars) and isogenic cpdA mutants (black bars) carrying a chromosomal
cpdA promoter-lacZ fusion. Values represent the mean  standard error of the mean of triplicate assays. The asterisk indicates that the values
for the designated cpdA mutants were significantly different (P  0.005) from the values for the corresponding isogenic cpdA strains. (B) EMSA
showing specific DNA binding of cAMP-Vfr to the cpdA promoter region. Radiolabeled probes (0.25 nM each), corresponding to different regions
of the cpdA promoter, were incubated in the absence () or presence of cAMP-Vfr (protein concentrations are given from left to right: 114, 13,
and 1 nM) for 15 min, followed by electrophoresis and phosphorimaging. Numbers indicate the distance (in bp) relative to the translational start
site. (C) DNase I footprinting of the cpdA promoter region by cAMP-Vfr. Samples contained a DNA fragment (0.4 nM) corresponding to 249
bp to 49 bp relative to the cpdA translational start codon; the bottom strand of the DNA probe was radiolabeled on a single end. Prior to
treatment with DNase I, the DNA probe was incubated in the absence () or presence of cAMP-Vfr (114, 13, or 1 nM). DNase I-generated
fragments were separated by electrophoresis and Maxam-Gilbert (A  G) sequencing ladders were made using the same DNA. The area of DNase
I cleavage altered by cAMP-Vfr is indicated by the arrows, and the DNA sequence of the top strand is shown. Numbers indicate the distance (in
bp) relative to the translational start site, and asterisks indicate positions of enhanced DNase I cleavage. Bold nucleotides indicate conservation
with the reported consensus Vfr binding site (22).
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when P. aeruginosa has established a chronic infection, perhaps
providing a means to escape host immune detection (32).
Thus, the ability to regulate cAMP levels through synthesis
(CyaB) and degradation (CpdA) may enable P. aeruginosa to
readily adapt to its surroundings.
Currently, the reason for the slow-growth, small-colony phe-
notype associated with the cpdA mutant is not clear as we have
ruled out the possibility that elevated cAMP levels or Vfr-
dependent transcriptional activity are responsible (Fig. 5). In
addition, the lack of detectable cGMP in wild-type and cpdA
mutant strains suggests that it is unlikely that altered cGMP
levels cause the growth phenotype. Interestingly, a recent study
has shown that the M. tuberculosis cAMP phosphodiesterase
Rv0805 can hydrolyze multiple phosphoester substrates, sug-
gesting that the growth defect in P. aeruginosa cpdA mutants
may reflect the involvement of CpdA in other metabolic path-
ways (37). In addition, Rv0805 was shown to localize to the M.
tuberculosis membrane and cell wall, suggesting a possible role
in membrane function (37). Increased antibiotic sensitivity and
elongated cell morphology of S. typhimurium and V. vulnificus
cpdA mutants, respectively, are consistent with the idea that
bacterial cAMP phosphodiesterases play an ancillary role in
cell membrane function (2, 24) and could account for the
slow-growth, small-colony phenotype of P. aeruginosa cpdA
mutants.
In this study, we used a combination of in vitro and in vivo
experiments to show that cpdA is a novel target of the cAMP-
Vfr regulon (Fig. 6). Although whole-genome transcriptional
profiling did not previously identify cpdA as being regulated by
cAMP or Vfr (59), different bacterial growth conditions used
in our study may explain this inconsistency. Our data clearly
show that cpdA transcription is activated by the cAMP-Vfr
complex in vivo. In turn, CpdA protein reduces cAMP levels
and, hence, cAMP-Vfr-dependent gene expression. This feed-
back mode of regulation would be advantageous in optimizing
the intracellular cAMP concentration and raises the question
as to whether there is a hierarchy of gene expression within the
cAMP-Vfr regulon. We propose that activation of cAMP syn-
thesis (in response to some as yet unknown host cue) would, in
turn, increase cAMP-Vfr levels and subsequent Vfr-dependent
virulence gene expression. The simultaneous upregulation of
cpdA by cAMP-Vfr would lead to subsequent degradation of
cAMP (signal attenuation) and would facilitate the finite ex-
pression of cAMP-Vfr dependent virulence genes.
Transcriptional regulation of cpdA also appears to occur in
other bacterial systems. For instance, within the P2 promoter
region of icc, a cpdA homolog in Haemophilus influenzae, a
putative CRP binding site has been identified, suggesting that
cAMP-CRP may regulate icc expression (29). In addition, it
was recently shown that in V. vulnificus, the cAMP-CRP com-
plex directly activates transcription of the cpdA gene (24).
Interestingly, in V. vulnificus, cpdA is part of the mutT-yqiB-
cpdA-yqiA operon whose expression requires a CRP binding
site located upstream of the mutT transcription start site
(24). In contrast, the region immediately upstream of P.
aeruginosa cpdA (500 to 100 bp relative to the cpdA start
codon) was sufficient for regulation of cpdA by cAMP-Vfr in
vivo (Fig. 6A). Furthermore, DNase I footprinting results
indicate that cAMP-Vfr directly binds to a region of the
cpdA promoter which corresponds to 104 bp to 80 bp
relative to the cpdA translational start codon (Fig. 6C).
Thus, it appears that differences in the locations of Vfr and
CRP binding sites relative to the cpdA coding sequence may
exist among bacterial species.
The finding that cAMP-Vfr controls cpdA transcription
raises the question as to whether there are additional modes of
CpdA regulation. Interestingly, cpdA translation from both P.
aeruginosa and E. coli initiates at a rare start codon, UUG (21).
It has been proposed that expression of E. coli cpdA may be
limited at the translational level based on the finding that
expression of E. coli cyaA, which also possesses the UUG start
codon, increases upon changing the start codon to GUG or the
more common AUG (40). Furthermore, there is evidence that
in E. coli, inorganic phosphate reduces cAMP phosphodiester-
ase activity in vivo (3) and that CpdA activity is inhibited by
both phosphate and succinate in vitro (34). However, we ob-
served that wild-type and cpdA mutant strains grew at similar
rates in minimal defined medium containing either succinate
or glucose, suggesting that succinate does not inhibit P. aerugi-
nosa CpdA activity in vivo. Nevertheless, further experiments
are needed to establish whether translation or enzyme activity
of P. aeruginosa CpdA is subject to regulation.
In summary, the results of this study establish the function of
P. aeruginosa CpdA as a cAMP phosphodiesterase and provide
evidence that cAMP degradation plays a central role in main-
taining the intracellular levels of cAMP in P. aeruginosa. Our
findings provide valuable, new insight as to how this bacterial
pathogen maintains control of virulence gene expression.
Furthermore, the finding that CpdA is regulated at the tran-
scriptional level has shed light on an additional mechanism
that contributes to cAMP homeostasis. These results not
only demonstrate the significance of cAMP phosphodiester-
ases in cAMP signaling but also open new areas of inquiry
regarding the contribution of cAMP phosphodiesterases to
other cellular processes.
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